» Articles » PMID: 27366006

Early Changes in the Serotype Distribution of Invasive Pneumococcal Isolates from Children After the Introduction of Extended-valent Pneumococcal Conjugate Vaccines in Korea, 2011-2013

Abstract

This study was performed to measure early changes in the serotype distribution of pneumococci isolated from children with invasive disease during the 3-year period following the introduction of 10- and 13-valent pneumococcal conjugate vaccines (PCVs) in Korea. From January 2011 to December 2013 at 25 hospitals located throughout Korea, pneumococci were isolated among children who had invasive pneumococcal disease (IPD). Serotypes were determined using the Quellung reaction, and the change in serotype distribution was analyzed. Seventy-five cases of IPD were included. Eighty percent of patients were aged 3-59 months, and 32% had a comorbidity that increased the risk of pneumococcal infection. The most common serotypes were 19A (32.0%), 10A (8.0%), and 15C (6.7%). The PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, and 6A) accounted for 14.7% of the total isolates and the PCV13 minus PCV7 types (1, 3, 5, 7F and 19A) accounted for 32.0% of the total isolates. Serotype 19A was the only serotype in the PCV13 minus PCV7 group. The proportion of serotype 19A showed decreasing tendency from 37.5% in 2011 to 22.2% in 2013 (P = 0.309), while the proportion of non-PCV13 types showed increasing tendency from 45.8% in 2011 to 72.2% in 2013 (P = 0.108). Shortly after the introduction of extended-valent PCVs in Korea, serotype 19A continued to be the most common serotype causing IPD in children. Subsequently, the proportion of 19A decreased, and non-vaccine serotypes emerged as an important cause of IPD. The impact of extended-valent vaccines must be continuously monitored.

Citing Articles

Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine.

Meroc E, Fletcher M, Hanquet G, Slack M, Baay M, Hayford K Microorganisms. 2023; 11(7).

PMID: 37512988 PMC: 10383425. DOI: 10.3390/microorganisms11071816.


Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong.

Mohanty S, Hu T, Yang G, Khan T, Owusu-Edusei K, Sukarom I Hum Vaccin Immunother. 2022; 18(5):2046433.

PMID: 35420975 PMC: 9196648. DOI: 10.1080/21645515.2022.2046433.


Effects of nasopharyngeal microbiota in respiratory infections and allergies.

Kang H, Kang J Clin Exp Pediatr. 2021; 64(11):543-551.

PMID: 33872488 PMC: 8566799. DOI: 10.3345/cep.2020.01452.


Regional variations in serotype distribution and vaccination status in children under six years of age with invasive pneumococcal disease in Germany.

Perniciaro S, Imohl M, Fitzner C, van der Linden M PLoS One. 2019; 14(1):e0210278.

PMID: 30625215 PMC: 6326516. DOI: 10.1371/journal.pone.0210278.


Genetic structures of invasive Streptococcus pneumoniae isolates from Korean children obtained between 1995 and 2013.

Yun K, Choi E, Lee H, Kang J, Kim K, Kim D BMC Infect Dis. 2018; 18(1):268.

PMID: 29884115 PMC: 5994121. DOI: 10.1186/s12879-018-3177-7.


References
1.
Iroh Tam P, Madoff L, Coombes B, Pelton S . Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine. Pediatrics. 2014; 134(2):210-7. PMC: 4187237. DOI: 10.1542/peds.2014-0473. View

2.
Lee J, Cho H, Kim K, Kim C, Kim D, Kim K . Etiology of invasive bacterial infections in immunocompetent children in Korea (1996-2005): a retrospective multicenter study. J Korean Med Sci. 2011; 26(2):174-83. PMC: 3030999. DOI: 10.3346/jkms.2011.26.2.174. View

3.
Waight P, Andrews N, Ladhani S, Sheppard C, Slack M, Miller E . Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015; 15(5):535-43. DOI: 10.1016/S1473-3099(15)70044-7. View

4.
Moore M, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett N . Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015; 15(3):301-9. PMC: 4876855. DOI: 10.1016/S1473-3099(14)71081-3. View

5.
. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000; 49(RR-9):1-35. View